This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Advanz Pharma, others see UK CMA thyroid drug-pricing fines upheld by appeal court

By Simon Zekaria ( May 8, 2025, 16:09 GMT | Insight) -- Fines imposed by the UK competition regulator on drugmaker Advanz Pharma and private equity groups Cinven and HgCapital over anticompetitive thyroid drug pricing were collectively upheld today by the UK Court of Appeal. The Competition and Markets Authority said the verdict represents an "important win" for the regulator in its enforcement battle over drug pricing.Sanctions imposed by the UK competition regulator on drugmaker Advanz Pharma and private equity groups Cinven and HgCapital over anticompetitive thyroid drug pricing were collectively upheld today by appeal judges....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections